AMPKγ2–Myosin Interaction: A Glycogen-Independent Trigger for PRKAG2 Cardiomyopathy

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: PRKAG2 cardiomyopathy. Intervention: Mavacamten.

Jiaxin Song; Yujiao Zhu; Yanjuan Lin; Yihua Bei

doi:10.1007/s12265-026-10835-y

August 28, 2026Journal of Cardiovascular Translational ResearchOpen Access

AMPKγ2–Myosin Interaction: A Glycogen-Independent Trigger for PRKAG2 Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Share

Key result

Early functional abnormalities in PRKAG2 cardiomyopathy are driven by AMPKγ2 association with cardiac myosin rather than glycogen accumulation, and are partially alleviated by mavacamten.

Key Points

Investigate whether direct interaction between AMPKγ2 and cardiac myosin initiates early contractile and electrophysiological abnormalities in PRKAG2 cardiomyopathy independently of glycogen accumulation.
Analyzed transgenic zebrafish expressing murine Prkag2 with the pathogenic R299Q point mutation at 3-to-6 days post-fertilization and adult stages.
Assessed electrophysiological and contractile responses following treatment with canonical AMPK activators (metformin, A-769662), cardiac myosin ATPase inhibitor mavacamten, or vmhcl knockdown.
Transgenic R299Q zebrafish hearts displayed myocyte hypertrophy, reduced diastole volume, slowed conduction velocity, and prolonged Ca²⁺ transients at 3-to-6 days post-fertilization, preceding adult glycogen accumulation.
The R299Q variant increased AMPKγ2 redistribution to the myofilament compartment and myofilament Ca²⁺ retention, which metformin and A-769662 failed to correct.
Mavacamten treatment or vmhcl knockdown reduced aberrant AMPKγ2–myosin binding and partially alleviated conduction slowing and action-potential prolongation.

Structured PICO

P

Population

Transgenic zebrafish expressing murine Prkag2 carrying the pathogenic R299Q point mutation

I

Intervention

Mavacamten or knockdown of myosin heavy chain-like (vmhcl)

Limitations

The long-term effects of myosin inhibition on ventricular systolic and diastolic function, conduction-system disturbance, and arrhythmia susceptibility remain unknown.
The molecular basis and normal physiological significance of the AMPKγ2-myosin association must be further defined.
The efficacy and safety of myosin inhibition must be further evaluated in established murine and large animal disease models.
Long-term effects of myosin inhibition on ventricular systolic and diastolic function, conduction-system disturbance, arrhythmia susceptibility, and established hypertrophy remain unknown

Implication

This editorial highlights recent preclinical evidence that PRKAG2 cardiomyopathy is driven by an abnormal AMPKγ2-myosin interaction rather than just glycogen accumulation, suggesting myosin modulation as a potential therapeutic strategy.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Song et al. (2026) conducted an editorial in PRKAG2 cardiomyopathy. Mavacamten was evaluated. Early functional abnormalities in PRKAG2 cardiomyopathy are driven by AMPKγ2 association with cardiac myosin rather than glycogen accumulation, and are partially alleviated by mavacamten.

synapsesocial.com/papers/6ad1159700741cc3fba7d66e https://doi.org/10.1007/s12265-026-10835-y

View Full Paper

Ask AI

Bookmark

Share

AMPKγ2–Myosin Interaction: A Glycogen-Independent Trigger for PRKAG2 Cardiomyopathy

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

AMPKγ2–Myosin Interaction: A Glycogen-Independent Trigger for PRKAG2 Cardiomyopathy

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More from Journal of Cardiovascular Translational Research

Keep reading

More from Journal of Cardiovascular Translational Research